Literature DB >> 21170264

Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers.

Joshua Z Press1, Kaitlyn Wurz, Barbara M Norquist, Ming K Lee, Christopher Pennil, Rochelle Garcia, Piri Welcsh, Barbara A Goff, Elizabeth M Swisher.   

Abstract

Microinvasive carcinomas and high-grade intraepithelial neoplasms are commonly discovered within the fallopian tube of BRCA1 mutation carriers at the time of risk-reducing salpingo-oophorectomy, suggesting that many BRCA1-mutated ovarian carcinomas originate in tubal epithelium. We hypothesized that changes in gene expression profiles within the histologically normal fallopian tube epithelium of BRCA1 mutation carriers would overlap with the expression profiles in BRCA1-mutated ovarian carcinomas and represent a BRCA1 preneoplastic signature. Laser capture microdissection of frozen sections was used to isolate neoplastic cells or histologically normal fallopian tube epithelium, and expression profiles were generated on Affymetrix U133 Plus 2.0 gene expression arrays. Normal-risk controls were 11 women wild type for BRCA1 and BRCA2 (WT-FT). WT-FT were compared with histologically normal fallopian tube epithelium from seven women with deleterious BRCA1 mutations who had foci of at least intraepithelial neoplasm within their fallopian tube (B1-FTocc). WT-FT samples were also compared with 12 BRCA1 ovarian carcinomas (B1-CA). The comparison of WT-FT versus B1-FTocc resulted in 152 differentially expressed probe sets, and the comparison of WT-FT versus B1-CA resulted in 4079 differentially expressed probe sets. The BRCA1 preneoplastic signature was composed of the overlap between these two lists, which included 41 concordant probe sets. Genes in the BRCA1 preneoplastic signature included several known tumor suppressor genes such as CDKN1C and EFEMP1 and several thought to be important in invasion and metastasis such as E2F3. The expression of a subset of genes was validated with quantitative reverse transcription-polymerase chain reaction and immunohistochemistry.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21170264      PMCID: PMC3003134          DOI: 10.1593/neo.101044

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  44 in total

1.  Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation.

Authors:  Wen Yue; Sanja Dacic; Quanhong Sun; Rodney Landreneau; Mingzhou Guo; Wei Zhou; Jill M Siegfried; Jian Yu; Lin Zhang
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

2.  Identification of Aurora-A as a direct target of E2F3 during G2/M cell cycle progression.

Authors:  Lili He; Hua Yang; Yihong Ma; W Jack Pledger; W Douglas Cress; Jin Q Cheng
Journal:  J Biol Chem       Date:  2008-09-07       Impact factor: 5.157

Review 3.  Profiling studies in ovarian cancer: a review.

Authors:  Rudolf S N Fehrmann; Xiang-Yi Li; Ate G J van der Zee; Steven de Jong; Gerard J Te Meerman; Elisabeth G E de Vries; Anne P G Crijns
Journal:  Oncologist       Date:  2007-08

4.  E2Fs mediate a fundamental cell-cycle deregulation in high-grade serous ovarian carcinomas.

Authors:  T De Meyer; I T G W Bijsmans; K K Van de Vijver; S Bekaert; J Oosting; W Van Criekinge; M van Engeland; N L G Sieben
Journal:  J Pathol       Date:  2009-01       Impact factor: 7.996

5.  Expression of chicken ovalbumin upstream promoter-transcription factor I (COUP-TFI) in bladder transitional cell carcinoma.

Authors:  Won Sik Ham; Joo Hyoung Lee; Ho Song Yu; Young Deuk Choi
Journal:  Urology       Date:  2008-04-02       Impact factor: 2.649

6.  Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma.

Authors:  Alicia A Tone; Heather Begley; Monika Sharma; Joan Murphy; Barry Rosen; Theodore J Brown; Patricia A Shaw
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

7.  NM23 as a prognostic biomarker in ovarian serous carcinoma.

Authors:  Bo Sung Youn; Dong-Su Kim; Jae Wook Kim; Young Tae Kim; Suki Kang; Nam Hoon Cho
Journal:  Mod Pathol       Date:  2008-04-11       Impact factor: 7.842

8.  Down-regulation of p57Kip2 induces prostate cancer in the mouse.

Authors:  Ren Jie Jin; Yongsoo Lho; Yongqing Wang; Mingfang Ao; Monica Patricia Revelo; Simon W Hayward; Marcia L Wills; Susan K Logan; Pumin Zhang; Robert J Matusik
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

9.  A chicken ovalbumin upstream promoter transcription factor I (COUP-TFI) complex represses expression of the gene encoding tumor necrosis factor alpha-induced protein 8 (TNFAIP8).

Authors:  Ling-juan Zhang; Xiao Liu; Philip R Gafken; Chrissa Kioussi; Mark Leid
Journal:  J Biol Chem       Date:  2008-12-26       Impact factor: 5.157

10.  CDKN1C/p57kip2 is a candidate tumor suppressor gene in human breast cancer.

Authors:  Pamela S Larson; Benjamin L Schlechter; Chia-Lin King; Qiong Yang; Chelsea N Glass; Charline Mack; Robert Pistey; Antonio de Las Morenas; Carol L Rosenberg
Journal:  BMC Cancer       Date:  2008-03-06       Impact factor: 4.430

View more
  13 in total

1.  The interconnectedness of cancer cell signaling.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

2.  Dinosaurs and ancient civilizations: reflections on the treatment of cancer.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

Review 3.  Evaluating the progenitor cells of ovarian cancer: analysis of current animal models.

Authors:  Shelby M King; Joanna E Burdette
Journal:  BMB Rep       Date:  2011-07       Impact factor: 4.778

4.  Perceptions of risk and reward in BRCA1 and BRCA2 mutation carriers choosing salpingectomy for ovarian cancer prevention.

Authors:  Talayeh S Ghezelayagh; Lauren E Stewart; Barbara M Norquist; Deborah J Bowen; Vivian Yu; Kathy J Agnew; Kathryn P Pennington; Elizabeth M Swisher
Journal:  Fam Cancer       Date:  2020-02-24       Impact factor: 2.375

5.  E2F3b over-expression in ovarian carcinomas and in BRCA1 haploinsufficient fallopian tube epithelium.

Authors:  Na Lu Smith; Piri Welcsh; Joshua Z Press; Kathy J Agnew; Rochelle Garcia; Elizabeth M Swisher
Journal:  Genes Chromosomes Cancer       Date:  2012-08-09       Impact factor: 5.006

6.  Epidermal growth factor-containing fibulin-like extracellular matrix protein 1 expression and regulation in uterine leiomyoma.

Authors:  Erica E Marsh; Shani Chibber; Ju Wu; Kendra Siegersma; Julie Kim; Serdar Bulun
Journal:  Fertil Steril       Date:  2015-12-17       Impact factor: 7.329

7.  Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715

8.  Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.

Authors:  Donavon Hiss
Journal:  J Oncol       Date:  2012-02-06       Impact factor: 4.375

Review 9.  New Predictive Biomarkers for Ovarian Cancer.

Authors:  Ghofraan Abdulsalam Atallah; Nor Haslinda Abd Aziz; Chew Kah Teik; Mohamad Nasir Shafiee; Nirmala Chandralega Kampan
Journal:  Diagnostics (Basel)       Date:  2021-03-07

10.  Modulation of folliculogenesis in adult laying chickens by bisphenol A and bisphenol S: Perspectives on ovarian morphology and gene expression.

Authors:  Fatma Eldefrawy; Hannah Shibo Xu; Elizabeth Pusch; Ashraf Karkoura; Mohamed Alsafy; Samir Elgendy; Susan M Williams; Kristen Navara; Tai L Guo
Journal:  Reprod Toxicol       Date:  2021-06-18       Impact factor: 3.421

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.